Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

IPSC

Century Therapeutics Inc

Feb 12 • 04:00PM ET

1.75

-0.04 -2.23 %

Healthcare • Biotechnology • USA • NASD

Peers: CRSP EDIT NTLA BEAM DNLI ARCT SGMO VERV CARR ZNTL

| Held by: VTI VXF AVSC

Index	-	P/E	-	EPS (ttm)	-0.31	Insider Own	38.40%	Shs Outstand	86.53M	Perf Week	4.79%
Market Cap	314.38M	Forward P/E	-	EPS next Y	-0.52	Insider Trans	0.31%	Shs Float	53.84M	Perf Month	-18.60%
Enterprise Value	226.59M	PEG	-	EPS next Q	-0.27	Inst Own	74.30%	Short Float	6.30%	Perf Quarter	210.67%
Income	-26.48M	P/S	2.77	EPS this Y	90.27%	Inst Trans	-2.52%	Short Ratio	1.87	Perf Half Y	228.21%
Sales	113.34M	P/B	0.86	EPS next Y	-229.79%	ROA	-8.36%	Short Interest	3.39M	Perf YTD	75.91%
Book/sh	2.04	P/C	2.37	EPS next 5Y	29.46%	ROE	-14.23%	52W High	2.71 -35.42%	Perf Year	134.05%
Cash/sh	0.74	P/FCF	-	EPS past 3/5Y	2.61% 18.46%	ROIC	-12.17%	52W Low	0.34 412.00%	Perf 3Y	-61.11%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	88.65%	Volatility	10.57% 13.52%	Perf 5Y	-
Dividend TTM	-	EV/Sales	2.00	EPS Y/Y TTM	83.30%	Oper. Margin	-20.00%	ATR (14)	0.22	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	6.25	Sales Y/Y TTM	4121.12%	Profit Margin	-23.36%	RSI (14)	48.65	Recom	1.67
Dividend Gr. 3/5Y	- -	Current Ratio	6.25	EPS Q/Q	-8.00%	SMA20	-14.47%	Beta	1.76	Target Price	4.20
Payout	-	Debt/Eq	0.25	Sales Q/Q	-100.00%	SMA50	24.10%	Rel Volume	0.56	Prev Close	1.79
Employees	150	LT Debt/Eq	0.23	Earnings	Nov 13 BMO	SMA200	129.20%	Avg Volume	1.82M	Price	1.75
IPO	Jun 18, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-18.52% -	Trades		Volume	1,021,893	Change	-2.23%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-08-24	Initiated	Rodman & Renshaw	Buy	$6
Aug-28-23	Downgrade	JP Morgan	Overweight → Neutral	$28 → $5
Dec-27-22	Initiated	Chardan Capital Markets	Buy	$19
Oct-31-22	Initiated	Guggenheim	Buy	$15
Oct-10-22	Initiated	Canaccord Genuity	Buy	$28
May-23-22	Initiated	H.C. Wainwright	Buy	$27
May-12-22	Initiated	William Blair	Mkt Perform
Jul-13-21	Initiated	Piper Sandler	Overweight	$38
Jul-13-21	Initiated	JP Morgan	Overweight	$40
Jul-13-21	Initiated	BofA Securities	Buy	$34

Jan-30-26 02:58PM	Piper Sandler Highlights Century Therapeutics (IPSC) Cash Runway Through 2029, Upcoming IND Submission (Insider Monkey) -5.47%
Jan-22-26 12:00PM	Century Therapeutics (IPSC) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +13.24%
Jan-08-26 08:00AM	Century Therapeutics Secures Oversubscribed $135 Million Private Placement Financing to Support Lead Program, CNTY-813, a Potentially Curative Therapy for Type 1 Diabetes (GlobeNewswire) +36.15%
Jan-07-26 11:45AM	FDA Grants Breakthrough Therapy Designation to ALKS' Narcolepsy Drug (Zacks) +44.44%
08:55AM	Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain (Zacks)
08:55AM	Loading…
Dec-09-25 08:55AM	Why Fast-paced Mover Century Therapeutics (IPSC) Is a Great Choice for Value Investors (Zacks)
08:00AM	Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors (GlobeNewswire)
Nov-25-25 04:01PM	Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference (GlobeNewswire)
Nov-13-25 07:30AM	Century Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) -17.54%
07:00AM	Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes (GlobeNewswire)
Oct-14-25 04:01PM	Century Therapeutics to Present at Chardan's 9th Annual Genetic Medicines Conference (GlobeNewswire)
Aug-22-25 08:00AM	Century Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-14-25 04:01PM	Century Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-21-25 12:00PM	All You Need to Know About Century Therapeutics (IPSC) Rating Upgrade to Strong Buy (Zacks)
Jul-15-25 08:50AM	Despite Fast-paced Momentum, Century Therapeutics (IPSC) Is Still a Bargain Stock (Zacks)
08:50AM	Loading…
Jun-25-25 08:50AM	Century Therapeutics (IPSC) Is Attractively Priced Despite Fast-paced Momentum (Zacks)
Jun-06-25 08:50AM	Fast-paced Momentum Stock Century Therapeutics (IPSC) Is Still Trading at a Bargain (Zacks) +9.47%
May-28-25 04:01PM	Century Therapeutics Announces Two Upcoming Presentations at the EULAR 2025 Congress (GlobeNewswire)
May-15-25 08:15PM	Century Therapeutics, Inc. (IPSC) Q1 Earnings and Revenues Top Estimates (Zacks) +5.79% +8.23%
04:01PM	Century Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-14-25 05:10PM	Journey Medical Corporation (DERM) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -7.02%
May-13-25 05:25PM	Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-01-25 10:01AM	Century Therapeutics, Inc. (IPSC) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
08:20AM	Madrigal (MDGL) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
Apr-28-25 04:30PM	Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting (GlobeNewswire)
Apr-15-25 04:01PM	Century Therapeutics to Host Live Fireside Chat Focused on Newly Prioritized Preclinical Cell Therapy Programs for Autoimmune Diseases and Cancer on Tuesday, April 22, 2025 (GlobeNewswire)
Mar-25-25 12:00PM	Century Therapeutics (IPSC) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Mar-19-25 05:15PM	Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses Revenue Estimates (Zacks) -5.66%
04:01PM	Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Jan-21-25 07:00AM	Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders (GlobeNewswire)
07:00AM	Loading…
Nov-26-24 07:00AM	Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference (GlobeNewswire)
Nov-08-24 12:00PM	What Makes Century Therapeutics (IPSC) a New Buy Stock (Zacks)
Nov-05-24 10:15AM	Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +5.56%
09:05AM	Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
09:00AM	Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Nov-04-24 07:00AM	Century Therapeutics to Present at Guggenheim's Inaugural Healthcare Innovation Conference (GlobeNewswire)
Sep-26-24 07:00AM	Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer (GlobeNewswire)
Aug-08-24 08:50AM	Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Jul-09-24 12:00PM	Century Therapeutics (IPSC) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Jun-03-24 07:00AM	Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting (GlobeNewswire)
May-10-24 03:35PM	Century Therapeutics Inc (IPSC) Q1 2024 Earnings: Aligns with EPS Projections Amid Strategic ... (GuruFocus.com)
07:00AM	Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting (GlobeNewswire)
May-09-24 01:54PM	IPSC Stock Earnings: Century Therapeutics Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
08:40AM	Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-23-24 07:00AM	Century Therapeutics to Present at Chardan's 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit (GlobeNewswire)
Apr-11-24 08:25AM	Century buys a startup, raises funding in cell therapy expansion (BioPharma Dive) +7.14%
07:00AM	Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics (GlobeNewswire)
Apr-08-24 04:05PM	Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +6.08%
Mar-25-24 07:00AM	Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors (GlobeNewswire) -9.48%
Mar-19-24 07:00AM	Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference (GlobeNewswire)
Mar-14-24 01:52PM	IPSC Stock Earnings: Century Therapeutics Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) -7.20%
07:30AM	Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-08-24 11:55PM	Century Therapeutics Inc (IPSC) COO Adrienne Farid Sells 53,515 Shares (GuruFocus.com)
Mar-07-24 09:55AM	How Much Upside is Left in Century Therapeutics, Inc. (IPSC)? Wall Street Analysts Think 193.4% (Zacks) +6.30%
Mar-05-24 06:03PM	Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) +17.65%
Feb-01-24 07:00AM	Century Therapeutics to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference (GlobeNewswire)
Dec-09-23 12:00PM	Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion Edits (GlobeNewswire)
Dec-07-23 11:01AM	Century (IPSC) Up 36% on FDA Nod to Begin Phase I Lupus Study (Zacks) +8.37%
Dec-06-23 07:30AM	Century Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data from Phase 1 ELiPSE-1 trial of CNTY-101 in Relapsed or Refractory B-cell Lymphomas and Planned Phase 1 Study in Systemic Lupus Erythematosus (GlobeNewswire) +36.08%
07:30AM	Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus (GlobeNewswire)
Dec-05-23 08:55AM	Penny Stock Jackpots: 3 High-Stakes Picks With 10-Bagger Potential (InvestorPlace)
Nov-21-23 07:00AM	Century Therapeutics to Present at the Piper Sandler 35th Annual Healthcare Conference (GlobeNewswire)
Nov-14-23 03:58PM	FMR LLC Adjusts Position in Century Therapeutics Inc (GuruFocus.com)
Nov-09-23 08:29AM	Century Therapeutics Inc (IPSC) Reports Q3 2023 Financial Results (GuruFocus.com) -13.13%
07:01AM	Century Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
07:00AM	Century Therapeutics Appoints Brent Pfeiffenberger, Pharm.D., MBA, as Chief Executive Officer (GlobeNewswire)
07:00AM	Century Therapeutics and FUJIFILM Cellular Dynamics Announce Licenses for the Development and Commercialization of iPSC-Derived Cell Therapies in Autoimmune and Inflammatory Diseases (GlobeNewswire)
Nov-02-23 09:00AM	Century Therapeutics to Present Initial Clinical Data Supporting the Potential for a Multi-Dosing Strategy for CAR iNK Enabled by Allo-Evasion Edits at the 65th ASH Annual Meeting and Exposition (GlobeNewswire)
Sep-26-23 07:00AM	Century Therapeutics to Present at the Chardan 7th Annual Genetic Medicines Conference (GlobeNewswire)
Aug-09-23 08:50AM	Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:30AM	Century Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-01-23 06:48AM	Century Therapeutics (NASDAQ:IPSC) shareholders have endured a 71% loss from investing in the stock a year ago (Simply Wall St.)
May-12-23 06:11AM	Century Therapeutics First Quarter 2023 Earnings: Revenues Beat Expectations, EPS Lags (Simply Wall St.)
May-11-23 08:55AM	Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:30AM	Century Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-17-23 07:00AM	Century Therapeutics to Present at Chardans 7th Annual Genetic Medicines & Cell Therapy Manufacturing Virtual Summit (GlobeNewswire)
Apr-12-23 08:30AM	Century Therapeutics Announces Leadership Changes (GlobeNewswire) -7.91%
Mar-16-23 08:55AM	Century Therapeutics, Inc. (IPSC) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
07:30AM	Century Therapeutics Reports Full Year 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Mar-15-23 04:01PM	Century Therapeutics to Present at the AACR Annual Meeting 2023 (GlobeNewswire)
Feb-21-23 07:00AM	Century Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-08-23 07:30AM	Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 ELiPSE-1 Trial Evaluating CNTY-101 in Relapsed or Refractory CD19 Positive B-cell Lymphomas (GlobeNewswire)
Feb-01-23 07:00AM	Century Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Jan-17-23 09:35AM	After Plunging -29.84% in 4 Weeks, Here's Why the Trend Might Reverse for Century Therapeutics, Inc. (IPSC) (Zacks) -7.36%
Jan-09-23 10:46AM	Century Therapeutics becomes latest life sciences company to enact layoffs, narrow focus (American City Business Journals)
Jan-06-23 08:23AM	Century Therapeutics Announces Internal Portfolio Prioritization, Analyst Views It As Incrementally Positive (Benzinga)
Jan-05-23 04:01PM	Century Therapeutics Announces Internal Portfolio Prioritization to Extend Cash Runway Into 2026 (GlobeNewswire)
Jan-04-23 07:00AM	Century Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-08-22 10:02AM	Further weakness as Century Therapeutics (NASDAQ:IPSC) drops 12% this week, taking one-year losses to 39% (Simply Wall St.)
Nov-22-22 07:00AM	Century Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference (GlobeNewswire) +5.24%
Nov-11-22 07:00AM	Century Therapeutics Announces Presentation of Preclinical Data at the SITC 37th Annual Meeting and Provides Pipeline Updates (GlobeNewswire) -5.01%
Nov-10-22 08:45AM	Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +15.11%
07:30AM	Century Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Updates (GlobeNewswire)
Nov-02-22 07:05AM	Century Therapeutics to Host Virtual Research and Development Day on November 11, 2022 (GlobeNewswire)
Oct-05-22 04:05PM	Century Therapeutics to Present at the SITC 37th Annual Meeting (GlobeNewswire)
Oct-03-22 07:00AM	Century Therapeutics Announces Appointment of Daphne Quimi and Timothy Walbert to its Board of Directors (GlobeNewswire)
Sep-26-22 07:00AM	Century Therapeutics to Present at Chardans 6th Annual Genetic Medicines Conference (GlobeNewswire)
Sep-06-22 07:00AM	Century Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)

Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It focuses on harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Carr Douglas	SVP Finance & Operations	Feb 03 '26	Sale	1.82	323	589	514,551	Feb 05 04:14 PM
Cowan Chad	Chief Scientific Officer	Dec 22 '25	Buy	0.85	58,060	49,252	1,045,087	Dec 29 04:52 PM
Pfeiffenberger Brent	President and CEO	Dec 12 '25	Buy	0.58	52,000	30,352	3,322,990	Dec 16 06:38 PM
Carr Douglas	SVP Finance & Operations	Dec 08 '25	Sale	0.53	257	137	404,874	Dec 10 04:34 PM
Russotti Gregory	See Remarks	Dec 08 '25	Sale	0.53	526	280	390,982	Dec 10 04:34 PM
Pfeiffenberger Brent	Officer	Dec 08 '25	Proposed Sale	0.53	476	253		Dec 08 03:29 PM
Russotti Gregory	Officer	Dec 08 '25	Proposed Sale	0.53	526	280		Dec 08 03:17 PM
Cowan Chad	Chief Scientific Officer	Nov 20 '25	Sale	0.50	5,462	2,736	987,027	Nov 24 04:05 PM
Pfeiffenberger Brent	President and CEO	Nov 19 '25	Buy	0.50	35,000	17,328	3,271,453	Nov 20 06:02 PM
Cowan Chad	Officer	Nov 20 '25	Proposed Sale	0.50	5,462	2,739		Nov 20 03:15 PM
Pfeiffenberger Brent	President and CEO	Nov 17 '25	Sale	0.45	32,456	14,735	3,236,453	Nov 19 04:19 PM
Pfeiffenberger Brent	Officer	Nov 17 '25	Proposed Sale	0.45	32,456	14,732		Nov 17 04:16 PM
Carr Douglas	SVP Finance & Operations	Nov 03 '25	Sale	0.59	292	171	405,131	Nov 05 04:01 PM
Carr Douglas	SVP Finance & Operations	Sep 08 '25	Sale	0.50	263	132	405,423	Sep 10 05:34 PM
Pfeiffenberger Brent	President and CEO	Sep 08 '25	Sale	0.50	488	244	3,268,909	Sep 10 05:29 PM
Russotti Gregory	See Remarks	Sep 08 '25	Sale	0.50	539	270	391,508	Sep 10 05:28 PM
Pfeiffenberger Brent	Officer	Sep 08 '25	Proposed Sale	0.50	488	244		Sep 08 03:28 PM
Russotti Gregory	Officer	Sep 08 '25	Proposed Sale	0.50	539	269		Sep 08 03:11 PM
Pfeiffenberger Brent	Officer	Aug 18 '25	Proposed Sale	0.57	30,745	17,522		Aug 18 04:24 PM
Carr Douglas	SVP Finance & Operations	Aug 04 '25	Sale	0.53	296	158	405,686	Aug 06 04:13 PM
Carr Douglas	SVP Finance & Operations	Jun 09 '25	Sale	0.62	4,904	3,050	405,982	Jun 11 05:05 PM
Farid Adrienne	Chief Operations Officer	Jun 09 '25	Sale	0.62	552	343	250,141	Jun 11 05:05 PM
Pfeiffenberger Brent	President and CEO	Jun 09 '25	Sale	0.62	475	295	1,681,783	Jun 11 05:05 PM
Russotti Gregory	See Remarks	Jun 09 '25	Sale	0.62	526	327	392,047	Jun 11 05:04 PM
Pfeiffenberger Brent	Officer	Jun 09 '25	Proposed Sale	0.62	475	296		Jun 09 03:15 PM
Farid Adrienne	Officer	Jun 09 '25	Proposed Sale	0.62	552	343		Jun 09 03:13 PM
Russotti Gregory	Officer	Jun 09 '25	Proposed Sale	0.62	526	327		Jun 09 03:09 PM
Pfeiffenberger Brent	President and CEO	May 16 '25	Sale	0.55	29,552	16,135	1,682,258	May 20 04:19 PM
Pfeiffenberger Brent	Officer	May 16 '25	Proposed Sale	0.55	29,552	16,138		May 16 03:47 PM
Farid Adrienne	Chief Operations Officer	May 05 '25	Sale	0.55	1,024	563	250,693	May 07 04:38 PM
Carr Douglas	SVP Finance & Operations	May 05 '25	Sale	0.55	295	162	410,886	May 07 04:38 PM
Farid Adrienne	Officer	May 05 '25	Proposed Sale	0.55	1,024	563		May 05 03:39 PM
Pfeiffenberger Brent	President and CEO	Mar 10 '25	Sale	0.61	2,235	1,375	1,190,310	Mar 12 07:30 PM
Russotti Gregory	See Remarks	Mar 10 '25	Sale	0.61	2,360	1,451	272,573	Mar 12 07:28 PM
Farid Adrienne	Chief Operations Officer	Mar 10 '25	Sale	0.61	2,359	1,451	131,717	Mar 12 07:27 PM
Carr Douglas	SVP Finance & Operations	Mar 10 '25	Sale	0.61	1,240	763	315,556	Mar 12 07:26 PM
Pfeiffenberger Brent	Officer	Mar 10 '25	Proposed Sale	0.62	2,235	1,375		Mar 10 04:21 PM
Russotti Gregory	Officer	Mar 10 '25	Proposed Sale	0.62	2,360	1,452		Mar 10 04:21 PM
Farid Adrienne	Officer	Mar 10 '25	Proposed Sale	0.62	2,359	1,451		Mar 10 04:17 PM
Pfeiffenberger Brent	President and CEO	Feb 18 '25	Sale	0.78	34,712	27,179	1,192,545	Feb 20 04:00 PM
Pfeiffenberger Brent	Officer	Feb 18 '25	Proposed Sale	0.78	34,712	27,166		Feb 18 04:10 PM

AMLX Amylyx Pharmaceuticals Inc daily Stock Chart

Peers: BIIB VRTX BMRN ALNY SRPT NBIX ACAD SAGE RARE CYTK

| Held by: VTI IWM VXF IBB IWO XPH SCHA VTWO IWC IHE

Index	RUT	P/E	-	EPS (ttm)	-1.80	Insider Own	16.57%	Shs Outstand	109.77M	Perf Week	8.31%
Market Cap	1.55B	Forward P/E	-	EPS next Y	-1.18	Insider Trans	-2.43%	Shs Float	91.63M	Perf Month	11.67%
Enterprise Value	1.21B	PEG	-	EPS next Q	-0.35	Inst Own	96.04%	Short Float	15.01%	Perf Quarter	10.96%
Income	-149.28M	P/S	-	EPS this Y	65.00%	Inst Trans	25.40%	Short Ratio	8.97	Perf Half Y	69.52%
Sales	-0.67M	P/B	4.65	EPS next Y	23.60%	ROA	-48.67%	Short Interest	13.75M	Perf YTD	16.47%
Book/sh	3.02	P/C	4.49	EPS next 5Y	33.70%	ROE	-56.52%	52W High	17.49 -19.55%	Perf Year	298.58%
Cash/sh	3.13	P/FCF	-	EPS past 3/5Y	-42.83% -78.71%	ROIC	-44.30%	52W Low	2.60 441.15%	Perf 3Y	-58.74%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	574.28% 127.75%	Gross Margin	186.77%	Volatility	5.83% 7.76%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	52.85%	Oper. Margin	23660.30%	ATR (14)	0.97	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	13.70	Sales Y/Y TTM	-100.34%	Profit Margin	22448.42%	RSI (14)	49.81	Recom	1.10
Dividend Gr. 3/5Y	- -	Current Ratio	13.70	EPS Q/Q	65.50%	SMA20	-4.59%	Beta	-0.30	Target Price	21.11
Payout	-	Debt/Eq	0.02	Sales Q/Q	-100.00%	SMA50	4.41%	Rel Volume	0.44	Prev Close	14.35
Employees	123	LT Debt/Eq	0.01	Earnings	Nov 06 BMO	SMA200	33.96%	Avg Volume	1.53M	Price	14.07
IPO	Jan 07, 2022	Option/Short	Yes / Yes	EPS/Sales Surpr.	15.10% -100.00%	Trades		Volume	680,192	Change	-1.95%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-10-25	Resumed	Goldman	Buy	$10
Jun-24-25	Initiated	Guggenheim	Buy	$17
Jun-17-25	Initiated	Citigroup	Buy	$12
May-30-25	Initiated	TD Cowen	Buy
Apr-07-25	Upgrade	Mizuho	Neutral → Outperform	$7
Nov-18-24	Upgrade	Robert W. Baird	Neutral → Outperform	$3 → $11
Oct-23-24	Upgrade	BofA Securities	Neutral → Buy	$4.20 → $10
Mar-18-24	Downgrade	Mizuho	Buy → Neutral	$32 → $4
Mar-11-24	Downgrade	Robert W. Baird	Outperform → Neutral	$37 → $4
Mar-11-24	Downgrade	Leerink Partners	Outperform → Market Perform	$27 → $4
Mar-08-24	Downgrade	Goldman	Buy → Neutral
Mar-08-24	Downgrade	Evercore ISI	Outperform → In-line
Jan-03-24	Initiated	Robert W. Baird	Outperform	$37
Dec-12-23	Initiated	Deutsche Bank	Buy	$36
Jul-24-23	Upgrade	Goldman	Neutral → Buy	$45 → $49
Mar-31-23	Initiated	Mizuho	Buy	$52
Jan-05-23	Initiated	BofA Securities	Buy	$50
May-25-22	Initiated	Citigroup	Buy	$21
Apr-01-22	Downgrade	Goldman	Buy → Neutral	$36 → $10

Show Previous Ratings

Jan-29-26 05:05PM	HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS (PR Newswire)
Jan-19-26 08:01AM	Amylyx Nominates AMX0318 as Long-Acting GLP-1 Candidate for Rare Endocrine Disorders (Insider Monkey)
Jan-10-26 02:57PM	Amylyx Pharmaceuticals (AMLX) Announces the Selection of AMX0318 as Development Candidate for PBH and Other Rare Diseases (Insider Monkey)
Jan-09-26 07:16AM	Amylyx selects AMX0318 as development candidate for PBH (TipRanks)
Jan-08-26 07:00AM	Amylyx Pharmaceuticals Announces Nomination of AMX0318 as a Novel, Long-Acting GLP-1 Receptor Antagonist Development Candidate, Identified in Collaboration with Gubra A/S (Business Wire)
04:35AM	Loading…
Dec-12-25 04:35AM	Amylyx pins its next hopes on a niche drug in the obesity space (Pharma Voice)
Dec-05-25 09:00AM	Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial (Business Wire)
Nov-28-25 06:40PM	HALPER SADEH LLC ENCOURAGES AMYLYX PHARMACEUTICALS, INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS (PR Newswire)
Nov-10-25 09:40AM	Is Exact Sciences (EXAS) Stock Outpacing Its Medical Peers This Year? (Zacks)
Nov-06-25 02:12PM	Amylyx Pharmaceuticals Inc (AMLX) Q3 2025 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com) -5.89%
07:00AM	Amylyx Pharmaceuticals Reports Third Quarter 2025 Financial Results (Business Wire)
Nov-03-25 09:00AM	Amylyx Pharmaceuticals to Present at Upcoming Investor Conferences (Business Wire)
Oct-30-25 09:00AM	Amylyx Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 (Business Wire)
Oct-27-25 12:20PM	Halper Sadeh LLC Encourages Amylyx Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Oct-26-25 06:16AM	BofA Securities Lifts Amylyx Pharmaceuticals Inc. (AMLX) Price Target Amid Bolstered Balance Sheet (Insider Monkey)
12:00PM	Loading…
Oct-24-25 12:00PM	What Makes Amylyx Pharmaceuticals, Inc. (AMLX) a Strong Momentum Stock: Buy Now? (Zacks)
09:55AM	Wall Street Analysts See a 29.28% Upside in Amylyx Pharmaceuticals (AMLX): Can the Stock Really Move This High? (Zacks)
09:40AM	Has Amylyx Pharmaceuticals (AMLX) Outpaced Other Medical Stocks This Year? (Zacks)
Oct-16-25 04:43PM	Is AMLX Stock a Solid Choice Right Now? (Zacks)
Sep-10-25 12:06AM	Amylyx Pharmaceuticals Announces Pricing of $175 Million Underwritten Public Offering of Common Stock (Business Wire) +12.56%
Sep-09-25 04:01PM	Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock (Business Wire)
Aug-27-25 12:35PM	Amylyx culls rare neurological disorder programme after trial failure (Pharmaceutical Technology)
12:24PM	Amylyx Halts Rare Brain Disorder Drug Program After Disappointing Trial (Benzinga)
07:22AM	Amylyx drug comes up short; Sanofi names new CMO (BioPharma Dive)
07:00AM	Amylyx Pharmaceuticals to Discontinue ORION Program of AMX0035 for Progressive Supranuclear Palsy (PSP) (Business Wire)
Aug-19-25 12:07AM	H.C. Wainwright, Leerink Partners, and TD Cowen Reaffirm 'Buy' Ratings on Amylyx Pharmaceuticals, Inc. (AMLX) (Insider Monkey)
Aug-07-25 07:00AM	Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results (Business Wire)
Jul-31-25 09:00AM	Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025 (Business Wire)
Jul-15-25 08:58AM	Amylyx Pharmaceuticals Shares Promising Avexitide Data for Post-Bariatric Hypoglycemia at ENDO 2025, Phase 3 Enrollment Nears Completion (Insider Monkey)
Jul-14-25 11:52AM	Amylyx presents new exploratory analyses from avexitide trials for PBH (Clinical Trials Arena) +9.51%
05:00PM	Loading…
Jul-13-25 05:00PM	Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025 (Business Wire)
Jul-08-25 07:00AM	Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025 (Business Wire)
Jun-27-25 07:56AM	Why Shares in Amylyx Pharmaceuticals Soared This Week (Motley Fool)
Jun-25-25 03:27AM	After myriad failures, a new wave of ALS drugs approaches (Pharma Voice)
Jun-24-25 12:46PM	Amylyx Pharmaceuticals Gains FDA Fast Track for ALS Drug AMX0114 (Insider Monkey) +27.69%
Jun-03-25 07:00AM	Amylyx Pharmaceuticals Receives U.S. FDA Fast Track Designation for AMX0114 for the Treatment of Amyotrophic Lateral Sclerosis (Business Wire)
May-21-25 07:00AM	Amylyx Pharmaceuticals to Participate in Upcoming June Investor Conferences (Business Wire)
May-20-25 09:55AM	Wall Street Analysts See a 105.22% Upside in Amylyx Pharmaceuticals (AMLX): Can the Stock Really Move This High? (Zacks)
May-12-25 07:00AM	Amylyx Pharmaceuticals Announces Positive Long-Term Results from Phase 2 HELIOS Clinical Trial of AMX0035 in People with Wolfram Syndrome (Business Wire)
May-09-25 03:12AM	Amylyx Pharmaceuticals Inc (AMLX) Q1 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
May-08-25 07:00AM	Amylyx Pharmaceuticals Reports First Quarter 2025 Financial Results (Business Wire) -5.95%
May-07-25 06:00PM	Here are the major earnings before the open tomorrow (Seeking Alpha)
08:00AM	Amylyx Pharmaceuticals to Participate in Upcoming May Investor Conferences (Business Wire)
May-01-25 09:00AM	Amylyx Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025 (Business Wire)
06:06AM	Amylyx doses first subject in trial of post-bariatric hypoglycaemia treatment (Clinical Trials Arena)
Apr-30-25 07:00AM	Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia (Business Wire)
Apr-16-25 11:22AM	Is Amylyx Pharmaceuticals Inc. (NASDAQ:AMLX) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey)
Apr-11-25 08:11AM	Amgen says Imdelltra extended survival; Parker Institute adds new leaders (BioPharma Dive)
Apr-10-25 07:03AM	First subject dosed in Amylyxs Phase I trial of ALS therapy (Clinical Trials Arena)
Apr-09-25 07:00AM	Amylyx Pharmaceuticals Announces First Participant Dosed in Phase 1, Multiple Ascending Dose LUMINA Trial of AMX0114 in People Living with Amyotrophic Lateral Sclerosis (Business Wire) +5.44%
Apr-02-25 09:00AM	Amylyx Pharmaceuticals to Present at the 24th Annual Needham Virtual Healthcare Conference (Business Wire) +13.17%
Mar-27-25 10:17AM	Is Amylyx Pharmaceuticals (AMLX) The Hot Biotech Stock Under $5? (InsiderMonkey)
Mar-05-25 10:01AM	Amylyx Pharmaceuticals Inc (AMLX) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com) +11.63%
Mar-04-25 06:00AM	Amylyx Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Mar-03-25 07:18AM	Amylyx Pharmaceuticals Inc (AMLX) Q4 2024: Everything You Need To Know Ahead Of Earnings (GuruFocus.com) -8.54%
Feb-25-25 09:00AM	Amylyx Pharmaceuticals to Participate in Upcoming March Investor Conferences (Business Wire)
Feb-24-25 09:00AM	Amylyx Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on March 4, 2025 (Business Wire) -9.09%
Feb-10-25 09:00AM	Amylyx Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (Business Wire)
Jan-31-25 12:00PM	Amylyx Pharmaceuticals (AMLX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Jan-22-25 05:00AM	Intellia makes progress on HAE study; 2 more China drug deals (BioPharma Dive)
Jan-21-25 09:00AM	Amylyx Pharmaceuticals Announces FDA Has Lifted the Clinical Hold on AMX0114 Phase 1 Clinical Trial for the Treatment of Amyotrophic Lateral Sclerosis (Business Wire)
Jan-10-25 08:26AM	Amylyx Pharmaceuticals Announces Pricing of Public Offering of Common Stock (Business Wire) -7.16%
Jan-09-25 07:30PM	Amylyx Pharmaceuticals Announces Proposed Public Offering of Common Stock (Business Wire)
Jan-06-25 09:00AM	Amylyx Pharmaceuticals Appoints Dan Monahan as Chief Commercial Officer (Business Wire) -5.54%
Dec-30-24 02:52PM	Why Is Amylyx Pharmaceuticals (AMLX) Among the Best Biotech Penny Stocks to Invest in Now? (Insider Monkey)
Dec-05-24 07:35AM	Amylyx announces design of LUCIDITY clinical trial (TipRanks) -5.51%
Dec-04-24 07:30AM	Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia (Business Wire)
Nov-27-24 09:00AM	Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference (Business Wire) +5.32%
Nov-08-24 02:11AM	Amylyx Pharmaceuticals Inc (AMLX) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
01:33AM	Q3 2024 Amylyx Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
Nov-07-24 07:00AM	Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results (Business Wire) +5.14%
Nov-04-24 09:00AM	Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024 (Business Wire)
Oct-25-24 09:05PM	Perceptive Advisors LLC's Strategic Acquisition in Amylyx Pharmaceuticals Inc (GuruFocus.com) +8.37%
Oct-19-24 11:12AM	Amylyx Pharmaceuticals (AMLX): Leading Nano Cap in Neurodegenerative Disease Treatments (Insider Monkey)
Oct-18-24 07:34AM	Amylyxs AMX0035 shows promise in Phase II Wolfram syndrome trial (Clinical Trials Arena) +21.94%
07:26AM	Why Amylyx Pharmaceuticals Stock Was So Healthy This Week (Motley Fool)
07:04AM	PTC rebuffed again by EMA; Novartis licenses China-based biotechs cancer drug (BioPharma Dive)
Oct-17-24 09:00AM	Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome (Business Wire)
Oct-15-24 09:00AM	Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024 (Business Wire) +10.06%
Oct-09-24 05:32PM	Amylyx Pharmaceuticals Inc (AMLX) Q2 2024 Earnings Call Highlights: Strategic Pipeline ... (GuruFocus.com)
Sep-09-24 07:17PM	Director Karen Firestone Acquires 50,000 Shares of Amylyx Pharmaceuticals Inc (AMLX) (GuruFocus.com) +6.33% +5.56%
Sep-06-24 01:49AM	Director MILNE GEORGE M JR Acquires 100,000 Shares of Amylyx Pharmaceuticals Inc (AMLX) (GuruFocus.com) +7.73%
Aug-28-24 08:30AM	Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-12-24 09:00AM	Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer's Disease Pathology and Neurodegeneration (Business Wire)
Aug-08-24 07:00AM	Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results (Business Wire)
Aug-05-24 09:00AM	Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024 (Business Wire)
04:32AM	EC grants orphan drug status for Amylyxs Wolfram treatment (Pharmaceutical Technology)
Aug-02-24 09:00AM	Amylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram Syndrome (Business Wire)
Jul-10-24 10:53AM	Amylyx to rebuild pipeline with $35m Phase III ready GLP-1RA acquisition (Clinical Trials Arena) +25.45%
07:00AM	Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation (Business Wire)
03:00AM	Amylyx, with GLP-1 buy, doubles down on blood sugar drugs (BioPharma Dive)
Jul-09-24 04:01PM	Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide (Business Wire)
Jun-28-24 11:02AM	Amylyx ventures into metabolic diseases market with $35.1m deal (Pharmaceutical Technology)
Jun-04-24 09:00AM	Amylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (Business Wire)
May-14-24 07:25AM	Mizuho Cuts Price Target on Amylyx Pharmaceuticals to $3 From $4, Keeps Neutral Rating (MT Newswires)
May-10-24 03:54PM	Amylyx Pharmaceuticals Reports Q1 2024 Financial Results (GuruFocus.com) -7.14%
12:47PM	Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 08:15AM	Amylyx Pharmaceuticals, Inc. (AMLX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
07:00AM	Amylyx Pharmaceuticals Reports First Quarter 2024 Financial Results (Business Wire)
May-08-24 09:00AM	Amylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care Conference (Business Wire)

Amylyx Pharmaceuticals, Inc. is a commercial-stage biotechnology company, which engages in the provision of therapies for neurodegenerative diseases and amyotrophic lateral sclerosis (ALS). Its commercial product is Relyvrio, also known as Albrioza in Canada. The company was founded by Joshua Cohen and Justin Klee in 2013 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FRATES JAMES M	Chief Financial Officer	Feb 02 '26	Sale	14.65	3,557	52,097	173,547	Feb 04 04:05 PM
Cohen Joshua B	Co-Chief Executive Officer	Feb 02 '26	Sale	14.68	15,500	227,593	3,363,965	Feb 04 04:05 PM
Mazzariello Gina	Chief Legal Officer	Feb 02 '26	Sale	14.65	3,448	50,516	144,693	Feb 04 04:05 PM
Klee Justin B.	Co-Chief Executive Officer	Feb 02 '26	Sale	14.69	15,500	227,618	3,363,898	Feb 04 04:05 PM
Klee Justin B.	Officer	Feb 02 '26	Proposed Sale	14.68	15,500	227,617		Feb 02 04:10 PM
Cohen Joshua B	Officer	Feb 02 '26	Proposed Sale	14.68	15,500	227,593		Feb 02 04:10 PM
Mazzariello Gina	Officer	Feb 02 '26	Proposed Sale	14.65	3,448	50,515		Feb 02 04:10 PM
Frates James M	Officer	Feb 02 '26	Proposed Sale	14.65	3,557	52,097		Feb 02 04:10 PM
Cohen Joshua B	Co-Chief Executive Officer	Jan 15 '26	Option Exercise	7.57	197,182	1,492,668	3,514,814	Jan 20 09:46 PM
Cohen Joshua B	Co-Chief Executive Officer	Jan 16 '26	Option Exercise	7.57	2,818	21,332	3,381,439	Jan 20 09:46 PM
Cohen Joshua B	Co-Chief Executive Officer	Jan 15 '26	Sale	13.59	136,193	1,850,795	3,378,621	Jan 20 09:46 PM
Cohen Joshua B	Co-Chief Executive Officer	Jan 16 '26	Sale	13.83	1,974	27,299	3,379,465	Jan 20 09:46 PM
Klee Justin B.	Co-Chief Executive Officer	Jan 15 '26	Option Exercise	7.57	197,153	1,492,448	3,514,739	Jan 20 09:46 PM
Klee Justin B.	Co-Chief Executive Officer	Jan 16 '26	Option Exercise	7.57	2,847	21,552	3,381,393	Jan 20 09:46 PM
Klee Justin B.	Co-Chief Executive Officer	Jan 15 '26	Sale	13.58	136,193	1,849,869	3,378,546	Jan 20 09:46 PM
Klee Justin B.	Co-Chief Executive Officer	Jan 16 '26	Sale	13.89	1,995	27,701	3,379,398	Jan 20 09:46 PM
JUSTIN KLEE	Director	Jan 16 '26	Proposed Sale	13.52	1,995	26,972		Jan 16 04:05 PM
JOSHUA COHEN	Director	Jan 16 '26	Proposed Sale	13.52	1,974	26,688		Jan 16 04:03 PM
JOSHUA COHEN	Director	Jan 15 '26	Proposed Sale	14.07	136,193	1,916,236		Jan 15 04:17 PM
JUSTIN KLEE	Director	Jan 15 '26	Proposed Sale	14.07	136,193	1,916,236		Jan 15 04:14 PM
FRATES JAMES M	Chief Financial Officer	Jan 06 '26	Sale	11.11	3,326	36,954	177,104	Jan 08 04:05 PM
Cohen Joshua B	Co-Chief Executive Officer	Jan 06 '26	Sale	11.09	7,715	85,596	3,317,632	Jan 08 04:05 PM
Klee Justin B.	Co-Chief Executive Officer	Jan 06 '26	Sale	11.09	7,715	85,589	3,317,586	Jan 08 04:05 PM
Frates James M	Officer	Jan 06 '26	Proposed Sale	11.11	3,326	36,954		Jan 06 04:05 PM
Klee Justin B.	Officer	Jan 06 '26	Proposed Sale	11.09	7,715	85,590		Jan 06 04:05 PM
Cohen Joshua B	Officer	Jan 06 '26	Proposed Sale	11.09	7,715	85,597		Jan 06 04:04 PM
Firestone Karen	Director	Dec 23 '25	Buy	12.45	8,100	100,845	63,100	Dec 23 08:48 PM
Bedrosian Camille L	Chief Medical Officer	Dec 01 '25	Sale	14.35	6,580	94,418	175,756	Dec 03 04:39 PM
Bedrosian Camille L	Officer	Dec 01 '25	Proposed Sale	14.35	6,580	94,419		Dec 01 04:05 PM
Klee Justin B.	Co-Chief Executive Officer	Sep 30 '25	Sale	14.38	29,975	430,952	3,325,301	Oct 02 04:15 PM
Mazzariello Gina	Chief Legal Officer	Sep 30 '25	Sale	14.58	8,828	128,669	148,141	Oct 02 04:15 PM
FRATES JAMES M	Chief Financial Officer	Sep 30 '25	Sale	14.65	10,558	154,650	280,430	Oct 02 04:15 PM
Cohen Joshua B	Co-Chief Executive Officer	Sep 30 '25	Sale	14.35	29,933	429,469	3,325,347	Oct 02 04:15 PM
Bedrosian Camille L	Chief Medical Officer	Sep 30 '25	Sale	14.58	12,039	175,518	182,336	Oct 02 04:15 PM
Mazzariello Gina	Chief Legal Officer	Aug 13 '25	Sale	8.34	15,000	125,046	156,969	Aug 14 04:20 PM
Mazzariello Gina	Chief Legal Officer	Aug 12 '25	Sale	8.07	15,000	121,102	171,969	Aug 14 04:20 PM
GINA MAZZARIELLO	Officer	Aug 12 '25	Proposed Sale	7.82	30,000	234,600		Aug 12 04:25 PM
FRATES JAMES M	Chief Financial Officer	Mar 31 '25	Sale	3.47	10,896	37,806	290,988	Apr 02 05:22 PM
Bedrosian Camille L	Chief Medical Officer	Mar 31 '25	Sale	3.47	12,425	43,082	194,375	Apr 02 05:14 PM
Mazzariello Gina	Chief Legal Officer	Mar 31 '25	Sale	3.48	9,192	31,954	187,969	Apr 02 05:12 PM
Cohen Joshua B	Co-Chief Executive Officer	Mar 31 '25	Sale	3.47	21,490	74,482	3,355,280	Apr 02 04:57 PM
Klee Justin B.	Co-Chief Executive Officer	Mar 31 '25	Sale	3.46	21,490	74,454	3,355,276	Apr 02 04:52 PM
Zeiher Bernhardt G	Director	Mar 20 '25	Buy	3.70	10,000	37,005	10,000	Mar 24 04:15 PM
Klee Justin B.	Co-Chief Executive Officer	Mar 03 '25	Sale	3.15	4,595	14,483	3,196,648	Mar 05 04:35 PM
Cohen Joshua B	Co-Chief Executive Officer	Mar 03 '25	Sale	3.17	4,595	14,549	3,196,652	Mar 05 04:32 PM
Mazzariello Gina	Chief Legal Officer	Mar 03 '25	Sale	3.12	1,611	5,022	133,310	Mar 05 04:32 PM
Mazzariello Gina	Chief Legal Officer	Feb 24 '25	Sale	3.15	4,169	13,145	134,921	Feb 26 04:35 PM

Open in Screener

FOLD

Amicus Therapeutics Inc

Feb 12 • 04:00PM ET

14.33

+0.02 0.14 %

Healthcare • Biotechnology • USA • NASD

FOLD Amicus Therapeutics Inc daily Stock Chart

Peers: VRTX SRPT BMRN REGN CRSP EDIT PFE QURE AGIO BLUE

| Held by: VTI XBI IWM VB VBK VXF IWO IBB SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-0.04	Insider Own	1.74%	Shs Outstand	308.50M	Perf Week	0.35%
Market Cap	4.50B	Forward P/E	50.16	EPS next Y	0.29	Insider Trans	-7.60%	Shs Float	308.24M	Perf Month	0.07%
Enterprise Value	4.68B	PEG	-	EPS next Q	0.07	Inst Own	90.52%	Short Float	5.83%	Perf Quarter	53.76%
Income	-14.06M	P/S	7.51	EPS this Y	92.06%	Inst Trans	-3.29%	Short Ratio	1.64	Perf Half Y	99.30%
Sales	598.70M	P/B	19.19	EPS next Y	2099.96%	ROA	-1.70%	Short Interest	17.96M	Perf YTD	0.63%
Book/sh	0.75	P/C	17.05	EPS next 5Y	-	ROE	-6.87%	52W High	14.38 -0.35%	Perf Year	50.05%
Cash/sh	0.84	P/FCF	464.24	EPS past 3/5Y	41.55% 34.10%	ROIC	-2.12%	52W Low	5.51 160.07%	Perf 3Y	13.91%
Dividend Est.	-	EV/EBITDA	111.05	Sales past 3/5Y	20.03% 23.72%	Gross Margin	88.50%	Volatility	0.28% 0.24%	Perf 5Y	14.00%
Dividend TTM	-	EV/Sales	7.81	EPS Y/Y TTM	87.30%	Oper. Margin	5.77%	ATR (14)	0.08	Perf 10Y	168.86%
Dividend Ex-Date	-	Quick Ratio	2.09	Sales Y/Y TTM	21.28%	Profit Margin	-2.35%	RSI (14)	80.43	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.99	EPS Q/Q	352.49%	SMA20	0.24%	Beta	0.43	Target Price	14.50
Payout	-	Debt/Eq	1.92	Sales Q/Q	19.46%	SMA50	8.33%	Rel Volume	0.58	Prev Close	14.31
Employees	499	LT Debt/Eq	1.88	Earnings	Nov 04 BMO	SMA200	62.48%	Avg Volume	10.94M	Price	14.33
IPO	May 31, 2007	Option/Short	Yes / Yes	EPS/Sales Surpr.	55.44% 2.02%	Trades		Volume	6,397,508	Change	0.14%

Date	Action	Analyst	Rating Change	Price Target Change
Jan-22-26	Downgrade	Jefferies	Buy → Hold	$14.50
Dec-29-25	Downgrade	Leerink Partners	Outperform → Market Perform	$14.50
Dec-22-25	Downgrade	TD Cowen	Buy → Hold	$14.50
Dec-17-25	Initiated	Citigroup	Buy	$17
Sep-18-25	Upgrade	Needham	Hold → Buy	$14
Jul-17-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$108
Dec-13-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$17 → $12
Sep-06-24	Initiated	Jefferies	Buy	$18
May-30-24	Initiated	Wells Fargo	Overweight	$18
May-14-24	Upgrade	Guggenheim	Neutral → Buy	$13
Dec-19-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$15 → $20
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight	$14
Apr-13-22	Resumed	Goldman	Neutral	$11
Jan-14-22	Upgrade	SVB Leerink	Mkt Perform → Outperform	$12 → $16
Nov-15-21	Upgrade	Stifel	Hold → Buy	$12 → $16
Sep-30-21	Upgrade	JP Morgan	Neutral → Overweight	$16
Jul-19-21	Resumed	BTIG Research	Buy	$15
May-27-21	Initiated	Needham	Hold
May-21-21	Initiated	UBS	Buy	$16
Apr-14-21	Upgrade	Cantor Fitzgerald	Neutral → Overweight	$17

Show Previous Ratings

Feb-11-26 08:30AM	Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings? (Zacks)
Feb-03-26 08:00AM	Amicus Therapeutics Presents New Long-term Data for both Galafold (migalastat) and POMBILITI (cipaglucosidase alfa-atga) + OPFOLDA (miglustat) at the 22nd Annual WORLDSymposium 2026 (GlobeNewswire)
Feb-02-26 09:29AM	Jefferies Downgrades Amicus Therapeutics, Inc. (FOLD) to Buy And Lowers Price Target Amid Takeover Developments (Insider Monkey)
Jan-28-26 11:24AM	FOLD vs. RIGL: Which Rare Disease Biotech Stock Has Better Upside? (Zacks)
Jan-23-26 07:18AM	JANX Enters Global Oncology Collaboration With BMY, Stock Rises (Zacks)
11:55AM	Loading…
Jan-22-26 11:55AM	Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema (Zacks)
08:00AM	Here Are Thursdays Top Wall Street Analyst Research Calls: Alphabet, Callaway Golf, Datadog, Hyatt Hotels, Palantir, Texas Instruments, Verizon, and More (24/7 Wall St.)
Jan-21-26 10:46AM	ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission (Zacks)
10:12AM	NVO Expands Aspect Tie-Up to Advance Curative Diabetes Cell Therapies (Zacks)
08:36AM	MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know (Zacks)
Jan-19-26 12:53PM	Novartis' Ianalumab Wins Breakthrough Therapy Tag for Sjogren's Disease (Zacks)
08:01AM	Beat the Market the Zacks Way: Amicus, Micron, Amgen in Focus (Zacks)
Jan-16-26 11:15AM	Axsome Therapeutics Begins Phase III Study on AXS-14 for Fibromyalgia (Zacks)
11:01AM	FOLD Rises 136% in 6 Months: Should You Buy, Sell or Hold the Stock? (Zacks)
09:06AM	Erasca Stock Surges 42% in a Week: Here's What You Should Know (Zacks)
11:16AM	Loading…
Jan-15-26 11:16AM	Apellis Stock Crashes 23% in a Week: Here's What You Should Know (Zacks)
10:26AM	CG Oncology Stock Rallies Nearly 32% in a Week: Here is Why (Zacks)
06:47AM	One Rare Disease Biotech Posts 97% Margins but the Faster Growing Rival Just Turned Its First Profit (24/7 Wall St.)
Jan-14-26 10:52AM	TG Therapeutics Stock Rises 7% on Strong Q4 & 2025 Preliminary Results (Zacks)
10:18AM	PCRX, LG Chem Partner to Expand Exparel Reach Across the Asia-Pacific (Zacks)
Jan-13-26 01:28PM	ADMA Biologics Reports Preliminary 2025 Results, Ups 2026 Outlook (Zacks)
09:19AM	Sanofi's Teizeild Gets EU Approval for Treating Type 1 Diabetes (Zacks)
Jan-12-26 02:07PM	KRYS Reports Preliminary Results for 2025, Outlines 2026 Objectives (Zacks)
11:20AM	MDGL Secures Exclusive Global Right for MASH Treatment From PFE (Zacks)
10:14AM	PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates (Zacks)
09:33AM	Exelixis Posts Preliminary '25 Results, Issues '26 Outlook (Zacks)
Jan-09-26 11:46AM	AMRN Stock Up 17% as Preliminary Q4 Sales Beat Expectations (Zacks)
09:17AM	Bayer Accelerates Growth With siRNA, AI Deals and Pipeline Progress (Zacks)
Jan-08-26 12:49PM	Halper Sadeh LLC Encourages THS, FOLD, REVG Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
11:09AM	GLUE Stock Up 45% on Positive Interim Data on Inflammation Drug (Zacks)
09:44AM	Loading…
09:44AM	KRYS Stock Surges 57% in a Year: More Upside Potential in 2026? (Zacks)
08:50AM	EXEL Collaborates With Natera for Late-Stage Colorectal Cancer Study (Zacks)
Jan-07-26 09:53AM	OTLK Stock Crashes 67% in a Week: Here's What You Need to Know (Zacks)
Jan-06-26 11:47AM	Celcuity Stock Up 677% in 6 Months: What's Behind This Huge Increase? (Zacks)
11:15AM	Will Galafold Be Able to Aid FOLD's Top Line Heading Into Q4 Earnings? (Zacks)
10:50AM	Halper Sadeh LLC Encourages DBRG, FOLD, DVAX Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Jan-02-26 01:13PM	When healthcare M&A hits the cold chain (FreightWaves)
Dec-30-25 10:19AM	Halper Sadeh LLC Encourages EKSO, FOLD, WBD, CFLT Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Dec-29-25 07:52AM	Here Are Mondays Top Wall Street Analyst Research Calls: Doximity, KB Home, NVIDIA, Okta, On Holdings, Take-Two Interactive, Vail Resorts, and More (24/7 Wall St.)
Dec-23-25 06:45PM	Halper Sadeh LLC Encourages KPLT, FOLD, DHIL Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Dec-22-25 12:27PM	BioMarin snaps up Amicus Therapeutics for $4.8bn amid rare disease push (Pharmaceutical Technology)
12:15PM	A $4.8 Billion Reason to Buy BioMarin Stock Today (Barchart)
11:46AM	BioMarin to Buy Rare Disease Drugmaker Amicus Therapeutics for $4.8B (Zacks)
09:47AM	Arcellx initiated, Cummins upgraded: Wall Street's top analyst calls (The Fly)
09:29AM	Cytokinetics Wins FDA Approval for Cardiovascular Drug, Stock up (Zacks)
Dec-20-25 08:12AM	Amicus (FOLD) Flies to 52-Week High on $5-Billion BioMarin Merger (Insider Monkey)
Dec-19-25 04:32PM	Stocks to Watch Friday Recap: Lamb Weston, Intuitive Machines, Nike, Oracle (The Wall Street Journal) +30.21%
04:17PM	BioMarin Soars 18% After Folding In The $4.8 Billion Takeover Of Amicus (Investor's Business Daily)
12:41PM	Biotech Bombshell: BioMarin's $4.8B Bet Ignites Amicus Shares in Rare-Disease Power Play (GuruFocus.com)
12:17PM	Viatris Gets FDA Nod for Generic Sandostatin, Shares Regulatory Updates (Zacks)
11:57AM	BioMarin to Buy Rare-Disease Biotech Amicus Therapeutics for $4.8 Billion (The Wall Street Journal)
11:01AM	Stocks to Watch Friday: Lamb Weston, Intuitive Machines, Nike, Oracle (The Wall Street Journal)
10:55AM	BioMarin is Buying a Rare-Disease Biotech for Nearly $5 Billion. The Stock Is Jumping. (Barrons.com)
09:38AM	Stocks to Watch Friday: Nike, Oracle, FedEx, Sony (The Wall Street Journal)
09:33AM	BioMarin Pharmaceutical Scoops Up Amicus Therapeutics In $4.8 Billion Deal (Investor's Business Daily)
08:13AM	BioMarin to Buy Amicus Therapeutics for $4.8 Billion (The Wall Street Journal)
07:45AM	BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook (PR Newswire)
Dec-18-25 03:43AM	Zacks Industry Outlook Arcutis, Amicus and ANI (Zacks)
Dec-17-25 02:19PM	5 Biotech Stocks to Watch for Potential Upside (Zacks)
Dec-16-25 10:30AM	FOLD Shares Hit 52-Week High: Time to Buy, Sell or Hold the Stock? (Zacks)
08:53AM	GILD's Bictegravir and Lenacapavir Regimen for HIV Meets Primary Goal (Zacks)
Dec-15-25 09:59AM	RCUS Stock Down on Decision to Discontinue GILD Partnered Study (Zacks)
Dec-13-25 07:05AM	Amicus Therapeutics (FOLD) Soars to 52-Week High on 'Strong Buy' Reco (Insider Monkey)
Dec-12-25 09:55AM	Wall Street Analysts See a 60.61% Upside in Amicus Therapeutics (FOLD): Can the Stock Really Move This High? (Zacks) +6.57%
Dec-09-25 01:48PM	The Best Cheap Stocks Under $10 to Buy in December and 2026 (Zacks)
Dec-08-25 08:23AM	Beat the Market the Zacks Way: Veracyte, Las Vegas Sands, 3M in Focus (Zacks)
Dec-05-25 12:20PM	Surging Earnings Estimates Signal Upside for Amicus Therapeutics (FOLD) Stock (Zacks)
09:57AM	Can Galafold Continue to Drive Amicus' Top Line in 2026? (Zacks)
Dec-04-25 11:30AM	Amicus Therapeutics (FOLD) Up 6.4% Since Last Earnings Report: Can It Continue? (Zacks)
10:29AM	BMY Gains on News of Continuation of Alzheimer's Disease Study (Zacks)
Dec-02-25 02:20PM	BHC Stock Up as Solta Acquires Shibo's Aesthetics Distribution Business (Zacks)
Nov-26-25 09:55AM	Wall Street Analysts Think Amicus Therapeutics (FOLD) Could Surge 58.46%: Read This Before Placing a Bet (Zacks)
Nov-25-25 02:00PM	FDA Greenlights Novartis' Gene Replacement Treatment for SMA (Zacks)
Nov-24-25 01:53PM	BAYRYs Cardiovascular Drug Hits Goals in Late-Stage Study (Zacks)
Nov-21-25 10:15AM	NVS Ups Sales Projections as Key Drugs and Collaborations Fuel Growth (Zacks)
Nov-19-25 08:53AM	BAYRY Obtains Approval for Hormone Free VMS Treatment Lynkuet in the EU (Zacks)
Nov-14-25 08:11AM	GILD's Investigational Regimen for HIV Treatment Meets Primary Goal (Zacks)
Nov-13-25 01:46PM	Cytokinetics Gains 11.4% in a Week: Is There More Room for Growth? (Zacks)
Nov-11-25 12:52PM	Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus (Zacks)
Nov-10-25 08:16PM	Goldman Sachs Bullish on Amicus Therapeutics (FOLD) Following Q3 2025 Results (Insider Monkey)
09:55AM	Wall Street Analysts Believe Amicus Therapeutics (FOLD) Could Rally 76.32%: Here's is How to Trade (Zacks)
01:44AM	Zacks.com featured highlights include EverQuote, Amicus, Lam Research and Cboe Global Markets EverQuote, Amicus, Lam Research and Cboe Global Markets (Zacks)
Nov-07-25 10:40AM	Bet on These 4 Top-Performing Liquid Stocks to Maximize Returns (Zacks)
Nov-06-25 10:43AM	Catalyst Pharmaceuticals Q3 Earnings Beat, Firdapse Revenues Rise Y/Y (Zacks)
10:24AM	Viatris Tops Q3 Earnings & Revenue Estimates, Ups '25 Guidance (Zacks)
09:24AM	RXRX Q3 Loss Narrower Than Expected, Revenues Decline Y/Y (Zacks)
08:27AM	ADMA's Q3 Earnings Match Estimates, Revenues Beat on Strong Asceniv Sales (Zacks)
Nov-05-25 10:52AM	EXEL Tops Q3 Earnings Estimates, Cabometyx Fuels Product Sales (Zacks)
10:48AM	Ultragenyx Q3 Earnings and Sales Miss Estimates, Increase Y/Y (Zacks)
10:41AM	Madrigal Q3 Earnings Miss, MASH Drug Sales Drive Top Line, Stock Up (Zacks)
10:30AM	Novo Nordisk Q3 Earnings & Revenues Miss, GLP-1 Drugs Face US Hurdles (Zacks)
10:08AM	Amicus' Q3 Earnings Beat, Higher Product Sales Drive Y/Y Revenues (Zacks)
09:30AM	Compared to Estimates, Amicus Therapeutics (FOLD) Q3 Earnings: A Look at Key Metrics (Zacks)
Nov-04-25 04:07PM	Amicus Therapeutics Inc (FOLD) Q3 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
11:43AM	ZTS Q3 Earnings Beat, Revenues Miss, '25 Sales View Cut, Stock Down (Zacks)
09:54AM	Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks)
08:35AM	Amicus Therapeutics (FOLD) Beats Q3 Earnings and Revenue Estimates (Zacks)
07:29AM	Amicus Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates (GlobeNewswire)
Oct-31-25 01:45PM	Apellis Stock Down Despite Q3 Earnings and Revenues Beat Estimates (Zacks)

Amicus Therapeutics, Inc. is a biotechnology company, which focuses on discovering, developing, and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Campbell Bradley L	President and CEO	Jan 20 '26	Option Exercise	6.10	75,000	457,500	1,096,180	Jan 22 07:26 PM
Campbell Bradley L	President and CEO	Jan 20 '26	Sale	14.31	75,000	1,073,182	1,021,180	Jan 22 07:26 PM
BRADLEY CAMPBELL	Director	Jan 20 '26	Proposed Sale	14.33	75,000	1,074,750		Jan 20 04:26 PM
Clark David Michael	Chief People Officer	Dec 19 '25	Sale	14.17	25,642	363,380	245,690	Dec 23 04:16 PM
DAVID CLARK	Officer	Dec 19 '25	Proposed Sale	10.89	25,642	279,241		Dec 19 04:22 PM
Campbell Bradley L	President and CEO	Dec 15 '25	Option Exercise	9.03	70,426	635,947	1,207,708	Dec 17 06:21 PM
Campbell Bradley L	President and CEO	Dec 15 '25	Sale	10.86	77,926	846,011	1,129,782	Dec 17 06:21 PM
Clark David Michael	Chief People Officer	Dec 15 '25	Sale	11.00	25,643	282,073	271,332	Dec 17 06:19 PM
BRADLEY CAMPBELL	Director	Dec 15 '25	Proposed Sale	10.55	77,926	822,119		Dec 15 04:32 PM
DAVID CLARK	Officer	Dec 15 '25	Proposed Sale	10.55	25,643	270,534		Dec 15 04:17 PM
Campbell Bradley L	President and CEO	Dec 01 '25	Option Exercise	9.03	14,587	131,721	1,151,869	Dec 03 08:11 PM
Campbell Bradley L	President and CEO	Dec 01 '25	Sale	10.01	14,587	146,011	1,137,282	Dec 03 08:11 PM
BRADLEY CAMPBELL	Director	Dec 01 '25	Proposed Sale	9.93	14,587	144,849		Dec 01 04:19 PM
Castelli Jeff	Chief Development Officer	Nov 24 '25	Option Exercise	9.03	50,000	451,500	515,476	Nov 26 09:18 PM
Castelli Jeff	Chief Development Officer	Nov 24 '25	Sale	10.16	76,158	773,659	439,318	Nov 26 09:18 PM
Clark David Michael	Chief People Officer	Nov 24 '25	Sale	10.10	25,643	258,933	296,975	Nov 26 09:17 PM
Campbell Bradley L	President and CEO	Nov 24 '25	Option Exercise	9.03	14,587	131,721	1,151,869	Nov 26 09:17 PM
Campbell Bradley L	President and CEO	Nov 24 '25	Sale	10.04	14,587	146,522	1,137,282	Nov 26 09:17 PM
Rosenberg Ellen	Chief Legal Officer	Nov 24 '25	Option Exercise	5.80	36,000	208,930	543,710	Nov 26 09:16 PM
Rosenberg Ellen	Chief Legal Officer	Nov 25 '25	Option Exercise	5.13	36,000	184,680	543,710	Nov 26 09:16 PM
Rosenberg Ellen	Chief Legal Officer	Nov 26 '25	Option Exercise	5.13	23,621	121,176	531,331	Nov 26 09:16 PM
Rosenberg Ellen	Chief Legal Officer	Nov 24 '25	Sale	10.06	36,000	362,268	507,710	Nov 26 09:16 PM
Rosenberg Ellen	Chief Legal Officer	Nov 25 '25	Sale	10.00	36,000	360,000	507,710	Nov 26 09:16 PM
Rosenberg Ellen	Chief Legal Officer	Nov 26 '25	Sale	10.00	23,621	236,210	507,710	Nov 26 09:16 PM
ELLEN ROSENBERG	Officer	Nov 26 '25	Proposed Sale	9.87	23,621	233,139		Nov 26 04:18 PM
ELLEN ROSENBERG	Officer	Nov 25 '25	Proposed Sale	9.89	36,000	356,040		Nov 25 04:27 PM
JEFFREY CASTELLI	Officer	Nov 24 '25	Proposed Sale	9.56	76,158	728,070		Nov 24 04:25 PM
DAVID CLARK	Officer	Nov 24 '25	Proposed Sale	9.56	25,643	245,147		Nov 24 04:24 PM
BRADLEY CAMPBELL	Director	Nov 24 '25	Proposed Sale	9.56	14,587	139,452		Nov 24 04:24 PM
ELLEN ROSENBERG	Officer	Nov 24 '25	Proposed Sale	9.56	36,000	344,160		Nov 24 04:23 PM
Clark David Michael	Chief People Officer	Nov 04 '25	Sale	9.51	25,643	243,860	322,618	Nov 05 04:05 PM
DAVID CLARK	Officer	Nov 04 '25	Proposed Sale	8.86	25,643	227,197		Nov 04 04:33 PM
Campbell Bradley L	President and CEO	Feb 19 '25	Option Exercise	9.03	400	3,612	1,151,057	Feb 21 07:27 PM
Campbell Bradley L	President and CEO	Feb 19 '25	Sale	10.00	400	4,000	1,150,657	Feb 21 07:27 PM
BRADLEY CAMPBELL	Director	Feb 19 '25	Proposed Sale	9.85	400	3,940		Feb 19 04:36 PM

IPSC

Century Therapeutics Inc

AMLX

Amylyx Pharmaceuticals Inc

FOLD

Amicus Therapeutics Inc

Upgrade your FINVIZ experience